PLB-1004
- Generic Name
- PLB-1004
Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure
Phase 3
Not yet recruiting
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Avistone Biotechnology Co., Ltd.
- Target Recruit Count
- 278
- Registration Number
- NCT06970782
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Phase 2
Recruiting
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Avistone Biotechnology Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06574347
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Avistone Biotechnology Co., Ltd.
- Target Recruit Count
- 156
- Registration Number
- NCT06343064
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.
Phase 3
Not yet recruiting
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Avistone Biotechnology Co., Ltd.
- Target Recruit Count
- 327
- Registration Number
- NCT06281964
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Avistone Biotechnology Co., Ltd.
- Target Recruit Count
- 81
- Registration Number
- NCT06046495
- Locations
- 🇺🇸
University of California-Davis, Sacramento, California, United States
🇺🇸Research Site, Seattle, Washington, United States
🇺🇸Nebraska Cancer Specialists, Omaha, Nebraska, United States
A Phase â…¡ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Avistone Biotechnology Co., Ltd.
- Target Recruit Count
- 157
- Registration Number
- NCT06015503
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Avistone Biotechnology Co., Ltd.
- Target Recruit Count
- 91
- Registration Number
- NCT05347628
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath